PXL770 is not a peptide. It is a synthetic small molecule, a thienopyridone derivative (C₂₃H₁₈ClNO₃S, 423.91 g/mol, CAS (Chemical Abstracts Service registry number) 1523493-53-9), developed for oral administration by the French biotech company Poxel SA. Research-reagent catalogues often file it alongside metabolic peptides, but chemically and pharmacologically it belongs to a different class: no injection required, no peptidase hydrolysis, its own hepatic metabolism profile.

The key distinction: direct vs indirect AMPK activation

AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme complex (α, β, γ subunits) that acts as the cell's fuel gauge. When the ATP/AMP ratio falls, AMPK switches metabolism from storage to expenditure: it suppresses de novo lipogenesis by phosphorylating acetyl-CoA carboxylase, activates fatty-acid oxidation, and restrains mTORC1.[5]

Historically AMPK was activated indirectly. Metformin, AICAR and thiazolidinediones raise AMPK activity by altering the cell's energy state (for instance by inhibiting respiratory complex I), the enzyme responds to a secondary signal. That implies a broad off-target footprint, because what changes is not the kinase but the entire cellular energy balance.

PXL770 was positioned as a first-in-class direct allosteric AMPK activator: the molecule binds the enzyme complex itself and stabilises its active conformation without requiring a change in AMP levels. That distinction, not "another metabolic drug", is what made the compound scientifically interesting.

What the human research actually showed

This is an uncommon case where a research compound went far enough to give an honest answer, and the answer was mixed.

Phase 1b (Cell Reports Medicine, 2021). In people with insulin resistance and non-alcoholic fatty liver disease, PXL770 reduced de novo lipogenesis, confirming that the intended mechanism engages in humans, not only in cell culture.[2]

Phase 2a STAMP-NAFLD (Lancet Gastroenterology & Hepatology, 2021). A randomised, double-blind, placebo-controlled trial: 120 participants, 15 US sites, 12 weeks, three dosing regimens versus placebo. The trial did not meet its primary endpoint. Mean relative change in hepatic fat content was −1.1% on placebo versus −14.3% (250 mg twice daily, p=0.084) and −14.7% (500 mg once daily, p=0.076). The separation approached, but did not cross, the significance threshold. The 250 mg once-daily arm showed no effect at all (−1.0%).[1]

It is worth stating plainly: PXL770 did not demonstrate efficacy in NAFLD. Press releases at the time framed the results as "positive" on the strength of secondary measures, liver enzymes, glycaemic parameters in the type 2 diabetes subgroup. The primary endpoint, the reason the trial was run, was not met. The most common adverse event was diarrhoea (17–23% versus 0% on placebo); there were no life-threatening events or treatment-related deaths.

The pivot to rare disease

After STAMP-NAFLD, Poxel effectively wound down the large NASH (non-alcoholic steatohepatitis) programme and redirected the compound to indications where preclinical data looked stronger.

Autosomal dominant polycystic kidney disease (ADPKD). In work published in Kidney International (2023), PXL770 dose-dependently reduced cyst growth in cell models, and in an inducible kidney-epithelium-specific Pkd1 knockout mouse reduced blood urea by 47%, cystic index by 26% and kidney-to-body-weight ratio by 35%, alongside reductions in proliferation, macrophage infiltration and fibrosis markers.[3] The FDA (US Food and Drug Administration) granted Orphan Drug Designation for ADPKD.

X-linked adrenoleukodystrophy / adrenomyeloneuropathy. In the Journal of Pharmacology and Experimental Therapeutics (2022), PXL770 lowered very-long-chain fatty acid C26:0 by roughly 90% in patient-derived cells, improved mitochondrial respiration and reduced pro-inflammatory gene expression; in vivo it reduced C26:0 in brain (−25%) and spinal cord (−32%) with improved locomotor function.[4] The FDA granted Fast Track and Orphan Drug Designation.

The logic of the pivot is clear: where a metabolic defect stems directly from one broken pathway that AMPK can bypass, an effect size too small for NAFLD may be large enough to matter. But it must be understood plainly: these data are preclinical, cells and mice, not humans.

Limitations and open questions

  • The largest clinical trial was negative on its primary endpoint. Any account of PXL770 as a "proven" agent contradicts the published record.
  • Efficacy in the rare-disease indications has not been tested in humans. Orphan and Fast Track designations are regulatory acceleration mechanisms, not evidence of efficacy.
  • AMPK isoform selectivity. AMPK exists as many α/β/γ subunit combinations with different tissue distributions; how selectively PXL770 engages individual complexes remains open.
  • Long-term safety is unknown. The longest published human study ran 12 weeks.
  • Gastrointestinal tolerability was the main dose-limiting issue in the clinic.

Context

PXL770 is best read alongside SLU-PP-332, another small molecule that acts on metabolism through ERR nuclear receptors rather than a kinase. Both illustrate the same research strategy, pharmacologically mimicking the metabolic consequences of energy deficit. The difference is that PXL770 reached randomised human trials and produced a testable (if negative) answer, while SLU-PP-332 remains strictly preclinical. Other metabolic-pathway compounds are listed under Metabolic compounds.

Status

PXL770 is a research-use-only laboratory reagent. It is not a medicine and, as of publication, is not approved by any regulatory authority for the treatment of any human disease. It is not intended for human consumption, diagnosis, treatment or prevention, nor for veterinary use. The information here is reference material and is not medical advice or dosing guidance.